Leveraging Artificial Intelligence for the Prevention and Control of Infectious Diseases
Keywords:
Artificial Intelligence (AI), Machine Learning (ML), Antimicrobial peptide (AMPs), Antimicrobial susceptibility testing (AST)Abstract
Infection diseases caused by pathogenic microorganisms, such as bacteria, viruses, fungi, and parasite, continue to be a significant global health concern. This problem is made worse by the lack of quick diagnostics and the rapid increase in antibiotic resistance. Through quantitative modelling, sequencing and the programmability of biology molecules like proteins, peptides and nucleic acids, advances in systems and synthetic biology have made it possible to develop new anti-infective treatments, vaccines, and diagnostic platforms. By enabling data-driven prediction, optimization, and analysis across various biology domains, these developments are being accelerated by powerful tool like machine learning and AI. Machine learning models have contributed to the discovery of new antimicrobial compounds, including graph-based predications, aptamers, and other alternative modalities. Additionally, machine learning techniques have guided the development of vaccines, predicated virulence and immunogenicity, enhanced our understanding of host-pathogen interactions, and enabled the automatic interpretation of data from mass spectrometry sequencing and microscopy. CRISPR- based sensors, toehold switches, and rapid susceptibility testing is example of AI-integrated diagnostics that have the potential to detect emerging infections more quickly, portably, and easily. Notwithstanding advancements, problems with data quality, model generalizability, bias reduction and clinical validation still exist. It is anticipated that as synthetic biology and next generation AI continue to be integrated, therapeutic discovery will progress, diagnostic precision will increase, and global capabilities for fighting infectious diseases will be strengthened
Downloads
References
[1.] J. Verhoef, K. Van Kessel, and H. Snippe, “Immune Response in Human Pathology: Infections Caused by Bacteria, Viruses, Fungi, and Parasites,” Nijkamp Parnham’s Princ. Immunopharmacol. Fourth Revis. Ext. Ed., pp. 165–178, Jan. 2019, doi: 10.1007/978-3-030-10811-3_10/FIGURES/5.
[2] M. Soares, “Symbiotic relationships in environments of change: The potential of biological interactions in Artificial Intelligence,” Mar. 2025.
[3] A. A. Theodosiou and R. C. Read, “Artificial intelligence, machine learning and deep learning: Potential resources for the infection clinician,” J. Infect., vol. 87, no. 4, pp. 287–294, Oct. 2023, doi: 10.1016/J.JINF.2023.07.006.
[4] W. Al Borhani, “G216072 Aptameric Biosensors for the Detection of Apramycin and Amoxicillin Antibiotics in Water”.
[5] C. R. Chung, T. R. Kuo, L. C. Wu, T. Y. Lee, and J. T. Horng, “Characterization and identification of antimicrobial peptides with different functional activities,” Brief. Bioinform., vol. 21, no. 3, pp. 1098–1114, May 2020, doi: 10.1093/BIB/BBZ043.
[6] R. Sahragard, M. Arabfard, and A. Najafi, “Predicting host-pathogen interactions with machine learning algorithms: A scoping review,” Infect. Genet. Evol., vol. 130, p. 105751, Jun. 2025, doi: 10.1016/J.MEEGID.2025.105751.
[7] S. Abbara, Y. Crabol, J. G. de Bouillé, A. Dinh, and D. Morquin, “Artificial intelligence and infectious diseases: Scope and perspectives,” Infect. Dis. Now, vol. 55, no. 7, 2025, doi: 10.1016/j.idnow.2025.105131.
[8] C. Zhang et al., “Deep learning for microscopic examination of protozoan parasites,” Comput. Struct. Biotechnol. J., vol. 20, pp. 1036–1043, Jan. 2022, doi: 10.1016/J.CSBJ.2022.02.005.
[9] S. M. Castillo-Hair and G. Seelig, “Machine Learning for Designing Next-Generation mRNA Therapeutics,” Acc. Chem. Res., vol. 55, no. 1, pp. 24–34, 2022, doi: 10.1021/acs.accounts.1c00621.
[10] C. Dong, Y. Liu, J. Nie, X. Zhang, F. Yu, and Y. Zhou, “Artificial Intelligence in Infectious Disease Diagnostic Technologies,” Diagnostics 2025, Vol. 15, Page 2602, vol. 15, no. 20, p. 2602, Oct. 2025, doi: 10.3390/DIAGNOSTICS15202602.
[11] R. W. Peeling, D. L. Heymann, Y. Y. Teo, and P. J. Garcia, “Diagnostics for COVID-19: moving from pandemic response to control,” Lancet, vol. 399, no. 10326, pp. 757–768, Feb. 2022, doi: 10.1016/S0140-6736(21)02346-1.
[12] E. Wenzler, M. Maximos, T. E. Asempa, L. Biehle, A. N. Schuetz, and E. B. Hirsch, “Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists,” Pharmacotherapy, vol. 43, no. 4, pp. 264–278, Apr. 2023, doi: 10.1002/PHAR.2781;PAGE:STRING:ARTICLE/CHAPTER.
[13] D. J. Park, M. Woo Park, H. Lee, Y.-J. Kim, Y. Kim, and Y. H. Park, “Development of machine learning model for diagnostic disease prediction based on laboratory tests,” Sci. Reports |, vol. 11, p. 7567, 123AD, doi: 10.1038/s41598-021-87171-5.
[14] V. Hassija, V. Chamola, A. Mahapatra, A. Singal, D. Goel, and K. Huang, “Interpreting Black ‑ Box Models : A Review on Explainable Artificial Intelligence,” Cognit. Comput., pp. 45–74, 2024, doi: 10.1007/s12559-023-10179-8.
[15] D. A. Tuan, P. Vu, N. Uyen, T. Ho, N. Vo, and T. Nhan, “Hybrid Quorum Sensing and Machine Learning Systems for Precision Gene Regulation : Revolutionizing Synthetic Biology and Autonomous Therapeutic Applications,” pp. 1–55, 2024.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
